IP Library › Granted Patent US 12,577,311

Granted Patent B2

US 12,577,311 · App. 17/298,271 · Granted Mar 17, 2026

Chimeric antigen receptor factories and methods of use thereof

Inventors: Wayne A. Marasco (Brookline, MA); Quan Karen Zhu (Southborough, MA); Yufei Wang (Brookline, MA); Matthew Chang (Brookline, MA)

Assignee: Dana-Farber Cancer Institute, Inc.

C07K16/2875 A61K40/11 A61K40/31 A61K40/4232 A61K40/4244 A61P35/00 C07K16/30 C12N5/0636 A61K2239/13 A61K2239/28 A61K2239/29 A61K2239/56

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,577,311
App. No.: 17/298,271
Granted: Mar 17, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention is directed to chimeric antigen receptors and cells comprising the same, wherein the cells further secrete monoclonal antibodies locally at a tumor site.

Claims (97)

1 . An engineered immune cell comprising a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises an extracellular ligand binding domain comprising an antibody, or antigen-binding fragment thereof wherein the antibody, or antigen-binding fragment thereof comprises an antigen binding domain specific for carbonic anhydrase XI (CAIX) and an antigen binding domain specific for cluster of differentiation 70 (CD70), wherein the antigen binding domain specific for CAIX comprises a sequence consisting of a variable heavy chain (VH), comprising a CDR1, CDR2, and CDR3, and a variable light chain (VL) comprising a CDR1, CDR2, and CDR3; wherein the antigen binding domain specific for CAIX is selected from the group consisting of:

a) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISGSGGSTYYADSVKG (SEQ ID NO: 66), SHSSGGFDY (SEQ ID NO: 86), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGRGYNVH (SEQ ID NO: 47), GNTNRPS (SEQ ID NO: 67), and QSYDSSLSAWV (SEQ ID NO: 87),

b) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISANGGTTYYADSVKG (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGAGFDVH (SEQ ID NO: 56), GNTNRPS (SEQ ID NO: 67), and QSYDSRLSAWV (SEQ ID NO: 95),

c) A VH CDR1, CDR2, and CDR3 according to TYAMT (SEQ ID NO: 44), AVSGSGGSTYYADSVKG (SEQ ID NO: 64), GPVLRYGFDI (SEQ ID NO: 84), And a VL CDR1, CDR2, and CDR2 according to TGSRSNIGADYDVH (SEQ ID NO: 45), ANNNRPS (SEQ ID NO: 65), and QSYDSSLRAWV (SEQ ID NO: 85),

d) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISANGGTTYYADSVKG (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGAGYDVH (SEQ ID NO: 48), GNSNRPS (SEQ ID NO: 69), and QSYDRSLSWV (SEQ ID NO: 89),

e) A VH CDR1, CDR2, and CDR3 according to GFTFSSYA (SEQ ID NO: 49), ISGSGGST (SEQ ID NO: 70), ATYGDYGSLDY (SEQ ID NO: 90), And a VL CDR1, CDR2, and CDR3 according to SSNIGAGYD (SEQ ID NO: 50), ANN, and QSYDSSLRAWV (SEQ ID NO: 85),

f) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISGSGGSTYYADSVKG (SEQ ID NO: 66), AAAGFDY (SEQ ID NO: 91), And a VL CDR1, CDR2 and CDR3 according to TGSSSNIGRGYNVH (SEQ ID NO: 47), DDINRPS (SEQ ID NO: 71), and QSYDSSLRAWV (SEQ ID NO: 85),

g) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISGSGGSTYYADSVKG (SEQ ID NO: 66), SHSSGGFDY (SEQ ID NO: 86), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGRGYNVH (SEQ ID NO: 47), GNTNRPS (SEQ ID NO: 67), and QSYDSSLSAWV (SEQ ID NO: 87),

h) A VH CDR1, CDR2, and CDR3 according to NYAMT (SEQ ID NO: 52), LISYDGSVTHYTDSVKG (SEQ ID NO: 72), GSGYQE (SEQ ID NO: 92), And a VL CDR1, CDR2, and CDR3 according to GGNNIGSKSVE (SEQ ID NO: 53), YDSDRPS (SEQ ID NO: 73), and QVWDSSSDHHVV (SEQ ID NO: 93),

i) A VH CDR1, CDR2, and CDR3 according to GFTFSNYA (SEQ ID NO: 54), ISYDGSVT (SEQ ID NO: 74), and ARGSGYQEH (SEQ ID NO:94), And a VL CDR1, CDR2, and CDR3 according to NIGSKS (SEQ ID NO: 55), YDS, and QVWDSSSDHHVV (SEQ ID NO: 93),

j) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISANGGTTYYADSVKG (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR3 according to TGSRSNIGADYDVH (SEQ ID NO: 45), ANNNRPS (SEQ ID NO: 65), and QSYDSSLSAWV (SEQ ID NO: 87),

k) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISGSGGSTYYADSVKG (SEQ ID NO: 66), IGRYSSSLGY (SEQ ID NO: 96), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGRGYNVH (SEQ ID NO: 47), DNTNRPS (SEQ ID NO: 75), and QSYDSGLRWV (SEQ ID NO: 97),

l) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISGSGGSTYYADSVKG (SEQ ID NO: 66), YGDYGSLDY (SEQ ID NO: 98), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGAGYDVH (SEQ ID NO: 48), ANNNRPS (SEQ ID NO: 65), and QSYDSSLRAWV (SEQ ID NO: 85),

m) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISANGGTTYYADSVKG (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR3 according to TGTSSNIGAGYDVH (SEQ ID NO: 57), GNNNRPS (SEQ ID NO: 76), and QSYDKSLSWV (SEQ ID NO: 99),

n) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISGSGVSTYYADSVKG (SEQ ID NO: 77), YCSSTSCYRGMDV (SEQ ID NO: 100), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGAGYDVH (SEQ ID NO: 48), ANNNRPS (SEQ ID NO: 65), and QSYDSSLRAWV (SEQ ID NO: 85),

o) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISANGGTTYYADSVKG, (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGAGYDVH (SEQ ID NO: 48), GNNNRPS (SEQ ID NO: 76), and QSYDKSLTWV (SEQ ID NO: 101),

p) A VH CDR1, CDR2, and CDR3 according to SYGMH (SEQ ID NO: 58), VISYDGSNKYYADSVKG (SEQ ID NO: 78), GRAARPPFDY (SEQ ID NO: 102), And a VL CDR1, CDR2, and CDR3 according to SGSSSNIGSNYVY (SEQ ID NO: 59), RNNQRPS (SEQ ID NO: 79), and AAWDDSLNGVV (SEQ ID NO: 103),

q) A VH CDR1, CDR2, and CDR3 according to SYGMH (SEQ ID NO: 58), VISYDGSNKYYADSVKG (SEQ ID NO: 78), EAPYSSSLDAFDI (SEQ ID NO: 104), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGRGYNVH (SEQ ID NO: 47), GNSNRPS (SEQ ID NO: 69), and HSRDNNGHHI (SEQ ID NO: 105),

r) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO:); AISANGGTTYYADSVKG (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGAGYDVH (SEQ ID NO: 48), GNSNRPS (SEQ ID NO: 69), and QSYDSSLSAWV (SEQ ID NO: 87),

s) A VH CDR1, CDR2, and CDR3 according to IYAMS (SEQ ID NO: 60), AISGSGGGTYHADSVKG (SEQ ID NO: 80), FSAYSGYDL (SEQ ID NO: 106), and a VL CDR1, CDR2, and CDR3 according to TGSSSNIGRGYNVH (SEQ ID NO: 47), DNTNRPS (SEQ ID NO: 75), and QSYDSGLRWV (SEQ ID NO: 97),

t) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISANGGTTYYADSVKG (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR3 according to TGSSSNIGAGFDVH (SEQ ID NO: 56), GNNNRPS (SEQ ID NO: 76), and QSYDSSLSAWV (SEQ ID NO: 87),

u) A VH CDR1, CDR2, and CDR3 according to SYAMS (SEQ ID NO: 46), AISANGGTTYYADSVKG (SEQ ID NO: 68), NGNYRGAFDI (SEQ ID NO: 88), And a VL CDR1, CDR2, and CDR2 according to TGSSSNIGAGYDVH (SEQ ID NO: 48), GNTNRPS (SEQ ID NO: 67), and QSYDSTLRVWM (SEQ ID NO: 107),

v) A VH CDR1, CDR2, and CDR3 according to KYAMS (SEQ ID NO: 61), GISGSGGSTYYADSVKG (SEQ ID NO: 81), SSRSGYFLPLDY (SEQ ID NO: 108), And a VL CDR1, CDR2, and CDR3 according to QGNSLRYYYPS (SEQ ID NO: 62), GKNNRPS (SEQ ID NO: 82), and SSRDNTDNRVV (SEQ ID NO: 109), and

w) A VH CDR1, CDR2, and CDR3 according to SYGMH (SEQ ID NO: 58), AISGSGGSTYYADSVKG (SEQ ID NO: 66), AAVTGGFDP (SEQ ID NO: 110), And a VL CDR1, CDR2, and CDR3 according to GGDNIGRKSVH (SEQ ID NO: 63), DDRDRPS (SEQ ID NO: 83), and QVWDSSSKHYV (SEQ ID NO: 111),

wherein the antigen binding domain specific for CD70 comprises a sequence consisting of a variable heavy chain (VH), comprising a CDR1, CDR2, and CDR3, and a variable light chain (VL) comprising a CDR1, CDR2, and CDR3, wherein the antigen binding domain specific for CD70 is selected from the group consisting of:

a) A VH CDR1, CDR2, and CDR3 according to GFTVSNYA (SEQ ID NO: 158), KSGSDGRT (SEQ ID NO: 167), AKGIYDVTGSSFDS (SEQ ID NO: 174), And a VL CDR1, CDR2, and CDR3 according to SGSIASNY (SEQ ID NO: 160), EDN, and QSYDSGNRRV (SEQ ID NO: 176),

b) A VH CDR1, CDR2, and CDR3 according to GFTFSSYA (SEQ ID NO: 49), ISGSGGSR (SEQ ID NO: 165), ARGRGGHGMDV (SEQ ID NO:170), And a VL CDR1, CDR2, and CDR3 according to SSNIGSNY (SEQ ID NO: 155), RNN, and AAWDDSLNGLV (SEQ ID NO: 171),

c) A VH CDR1, CDR2, and CDR3 according to GGTFSSQA (SEQ ID NO: 156), IIPFFGVP (SEQ ID NO: 166), AVLKGRGNFDF (SEQ ID NO:172), And a VL CDR1, CDR2, and CDR3 according to YSVFHSPNNKNY (SEQ ID NO: 157), WAS, and QQRSNWPLT (SEQ ID NO:173),

d) A VH CDR1, CDR2, and CDR3 according to GFTVSNYA (SEQ ID NO: 158), KSGSDGRT (SEQ ID NO: 167), AKGIYDVTGSSFDS (SEQ ID NO: 174), And a VL CDR1, CDR2, and CDR3 according to ALPKKY (SEQ ID NO: 159), EDS, and YSTDSSGNHKV (SEQ ID NO: 175),

e) A VH CDR1, CDR2, and CDR3 according to GFTVSTSH (SEQ ID NO: 161), KDSGGKT (SEQ ID NO: 168), ARARPSDPYDGSGFDAFDI (SEQ ID NO: 177), And a VL CDR1, CDR2, and CDR3 according to SNNVGNQG (SEQ ID NO: 162), RNN, and SAWDSSLSAWV (SEQ ID NO: 178), and

f) A VH CDR1, CDR2, and CDR3 according to GFIFSDYY (SEQ ID NO: 163), IRSRRGET (SEQ ID NO: 169), ARHRKSFTDLDAFDL (SEQ ID NO: 179), and And a VL CDR1, CDR2, and CDR3 according to QDIGTD (SEQ ID NO: 164), KAS, and QHFNNYPAT (SEQ ID NO: 180).

2 . The engineered immune cell of claim 1 , wherein the CAR further comprises a transmembrane polypeptide and an intracellular signaling domain.

3 . The engineered immune cell of claim 2 , wherein the CAR further comprises a co-stimulatory domain.

4 . The engineered immune cell of claim 1 , wherein the engineered immune cell is further engineered to express and secrete a recombinant polypeptide.

5 . The engineered immune cell of claim 4 , wherein the recombinant polypeptide comprises an antibody or fragment thereof, or a cytokine.

6 . The engineered immune cell of claim 5 , wherein the cytokine is selected from the group consisting interleukin-12 (IL-12), interleukin-15 (IL-15),—and interleukin-18 (IL-18).

7 . The engineered immune cell of claim 1 , wherein the cell is selected from the group consisting of comprises a T cell, a natural killer (NK) cell, and a natural killer T (NKT) cell.

8 . The engineered immune cell of claim 7 , wherein the T cell is selected from the group consisting of CD4+, CD8+, and CD3+ panT cells.

9 . The engineered immune cell of claim 1 , wherein the antibody, or antigen-binding fragment thereof, specific for CAIX is selected from the group consisting of:

a) a VH according to amino acid sequence QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAI SGSGGSTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARSHSSG GFDYWGQGTLVTVSS (SEQ ID NO: 114), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGRGYNVHWYQQLPGTAPKLLIYGN TNRPSGVPDRFSGSKSGTSASLAITGLQAEDEGDY YCQSYDSSLSAW VF GGG TKLTVLG (SEQ ID NO: 115);

b) a VH according to amino acid sequence EVQLVQSGGGVVQPGGSLRLSCAASGFPFSS YAMSWVRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDIWGQGTMVTVSS (SEQ ID NO: 127), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGFDVHWY QQLPGTAPKLLIYGN TNRPSGVPDRFSGSKSGTSASLAITGLQAEDETDY YCQS YDSRLSAW VF GGG TKLTVLG (SEQ ID NO: 128);

c) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASEFTFGTY AMTWVRQAPGKGLEWVSA VSGSGGSTY YADSVKGRFTISRDNSRNTLYLQMNSLRADDTAVYYCAR GPVLRYGFDI WGQGTMVIVSS (SEQ ID NO: 112), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRITISCTGSRSNIGADYDVHW YQQLPGTAPKLLIY AN NNRPSGVPGRFSASKSGTSASLAISGLQAEDEADY YCQSYDSSLRAW VFGGG TKLAVLG (SEQ ID NO: 113);

d) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFPFSS YAMSWVRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDIWGQGTMVTVSS (SEQ ID NO: 116), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGS SASLAITGLQAEDEAHY YCQS YDRSLSW VFGGGT KLTVLG (SEQ ID NO: 117);

e) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFTFSSYAMSW VRQAPGKGLEWVSAI SGSGGSTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATYGDY GSLDY (SEQ ID NO: 118), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYANNNRPSGVPDRFSGSKSGTS ASLAITGLQAEDEADY YCQSYDSSLRAW VFGGG TKLAVLG (SEQ ID NO: 119);

f) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFTFSSYAMSW VRQAPGKGLEWVSAI SGSGGSTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARAAAG FDYWGQGTLVTVSS (SEQ ID NO: 120), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGRGYNVHWYQQLPGTAPKLLIYDD INRPSGVPHRFSGSKSGTSASLAITGLQAEDEADY YCQSYDSSLRAW VFGGGT KLAVLG (SEQ ID NO: 121);

g) a VH according to amino acid sequence QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAI SGSGGSTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARSHSSG GFDYWGQGTLVTVSS (SEQ ID NO: 114), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGRGYNVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTS ASLAITGLQAXDEGDY YCQSYDSSLSAW VFGGG TKLTVLG (SEQ ID NO: 122);

h) a VH according to amino acid sequence QVTLKESGGGVVQPGTSLRLSCAASGFTFSNYAMTWVRQAPGKGLEWVGLI SYDGSVTHYTDSVKGRFTISRDNAKNSLYLQMNTLRADDTAVY YCARGSGY QEHWGQGTLVTVSS (SEQ ID NO: 123), and

a VL according to amino acid sequence LPVLTQPPSVSVAPGQTARITCGGNNIGSKSVEW YQQKPGQAPVLVIY YDSD RPSGIPERFSGSNSGNTATLTISR VEAGDEADY YCQVWDSSSDHHV VFGGGT KLTVLG (SEQ ID NO: 124);

i) a VH according to amino acid sequence QVTLKESGGGVVQPGTSLRLSCAASGFTFSNY AMTWVRQAPGKGLEWVGLI SYDGSVTHYTDSVKGRFTISRDNAKNSLYLQMNTLRADDTAVY YCARGSGY QEH (SEQ ID NO: 125), and

a VL according to amino acid sequence LPVLTQPPSVSVAPGQTARITCGGNNIGSKS VHW YQQKPGQAPVLVIY YDSD RPSGIPERFSGSNSGNTATLTISR VEAGDEADY YCQVWDSSSDHHVV (SEQ ID NO: 126);

j) a VH according to amino acid sequence QVOELVOSGGGVVQPGGSLRLSCAASGFPFSS YAMSWVRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDIWGQGTMVTVSS (SEQ ID NO: 129), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRITISCTGSRSNIGADYDVHW YQQLPGTAPKLLIY AN NNRPSGVPDRFSGSKSGTSASLAITGLQAEDETDYFCQSYDSSLSAW VFGGGT KVTVLG (SEQ ID NO: 130);

k) a VH according to amino acid sequence QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAI SGSGGSTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCAKIGRYS SSLGYWGQGTLVTVSS (SEQ ID NO: 131), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGRGYNVHWYQQLPGTAPKLLIYDN TNRPSGVPARFSGSKSATSASLAITGLQADDEADY YCQSYDSGLRW VFGGGT KLTLLR (SEQ ID NO: 132);

l) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFTFSSYAMSW VRQAPGKGLEWVSAI YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATYGDY GSLDYWGQGTLVTVSS (SEQ ID NO: 133), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYAN NNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADY YCQSYDSSLRAW VFGGG TKLAVLG (SEQ ID NO: 134);

m) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFPFSS YAMSWVRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDIWGQGTMVTVSS (SEQ ID NO: 116), and

a VL according to amino acid sequence QSVLTQPPSVSGAPGQRITISCTGTSSNIGAGYDVHW YQQLPGAAPRVLIYGN NNRPSGVPDRFSGSKSGTSASLAITGLQSEDEADY YCQSYDKSLSWVFGGGT KLTVLR (SEQ ID NO: 135);

n) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFTFSSYAMSW VRQAPGKGLEWVSAI SGSGVSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCAKYCSST SCYRGMDVWGKGTLVTVSS (SEQ ID NO: 136),

and a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYAN NNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADY YCQSYDSSLRAW VFGGG TKLAVLG (SEQ ID NO: 134);

o) A VH according to amino acid sequence QVQLVOQSGGGLVRPGGSLRLSCAASGFPFSSYAMSWVRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDI WGQGTTVTVSS (SEQ ID NO: 137),

and a VL according to amino acid sequence QSVLTQPPSVSGAPGQRITISCTGSSSNIGAG YDVHW YQQVPGKAPKVVIYGN NNRPSGVPDRFSGSKSGASASLAITGLQTEDEADY YCQS YDKSLTW VFGGGT KVTVLG (SEQ ID NO: 138);

p) a VH according to amino acid sequence QVQOLVOSGGGVVQPGRSLRLSCAASGFTFSS YGMHW VRQAPGKGLEWVAV ISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARGRA ARPPFDYWGQGTLVTVSS (SEQ ID NO: 139),

and a VL according to amino acid sequence QPVLTQPPSASGTPGQRVTISCSGSSSNIGSNY VYWY QQLPGTAPKLPIYRNN QRPSGVPDRFSGSKSGTSASLAISGLRSEDEADY YCAAWDDSLNGVVFGGGT KLTVLR (SEQ ID NO: 140);

q) a VH according to amino acid sequence QVQOLVOSGGGVVQPGRSLRLSCAASGFTFSS YGMHW VRQAPGKGLEWVAV ISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCAREAPY SSSLDAFDIWGQGTMVTVSS (SEQ ID NO: 141),

and a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGRGYNVHWYQQLPGTAPKLLIYGN SNRPSGVPDRFSGSSSGNTASLTITGAQAEDEADY YCHSRDNNGHHIFGGGT KLTVLS (SEQ ID NO: 142);

r) a VH according to amino acid sequence QVOELVOSGGGVVQPGGSLRLSCAASGFPFSS YAMSWVRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDIWGQGTMVTVSS (SEQ ID NO: 143),

and a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWY QHLPGTAPKLLIYGN SNRPSGVPDRFSGSKSGTSASLAITGLQAEDETDYFCQSYDSSLSAW VFGGGT KVTVLG (SEQ ID NO: 144);

s) a VH according to amino acid sequence QVQLQESGGGLVQPGGSLRLSCAASGFTFSIY AMSWVRQAPGKGLEWVSAIS GSGGGT YHADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCAKFSAYS GYDLWGQGTLVTVSS (SEQ ID NO: 145),

and a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGRGYNVHWYQQLPGTAPKLLIYDN TNRPSGVPARFSGSKSATSASLTITGLQADDEADY YCQSYDSGLRW VFGGGT KLTLLG (SEQ ID NO: 146);

t) a VH according to amino acid sequence EVQLVQSGGGLVQPGGSLRLSCAASGFTFSS YAMSW VRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDIWGQGTTVTVSS (SEQ ID NO: 147),

and a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGFD VHWY QQLPGTAPRLLIYGN NNRPSGVPDRFSGSKSGTSASLAITGLQAEDETDYFCQSYDSSLSAW VFGGGT KVTVLR (SEQ ID NO: 148);

u) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFPFSS YAMSWVRQAPGKGLEWVSAI SANGGTTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCANNGNY RGAFDIWGQGTMVIVSS (SEQ ID NO: 149),

and a VL according to amino acid sequence QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGN TNRPSGVPDRFSGSKSGTSASLAIIGLQADDEADY YCQS YDSTLRVWMFGGG TKLTVLG (SEQ ID NO: 150);

v) a VH according to amino acid sequence QVQOLVOQSGGGLVQPGGSLRLSCAAPEFTFSK YAMSW VRQAPGKGLEWVSGI SGSGGSTY YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCAKSSRSG YFLPLDYWGQGTLVTVSS (SEQ ID NO: 151),

and a VL according to amino acid sequence SSELTQDPAVSVALGQTVRITCQGNSLRY Y YPSW Y QQKPGQAPVLVIYGKNN RPSGIPDRFSGSSSGNTASLTITGTQAEDEADY YCSSRDNTDNRVVFGGGTKL TVLG (SEQ ID NO: 152); and

w) a VH according to amino acid sequence EVQLVESGGGV VQPGRSLRLSCAASGFTFSS YGMHW VRQAPGKGLEWVSAI SGSGGSTY YADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVY YCARAAVT GGFDPWGQGTLVTVSS (SEQ ID NO: 153),

and a VL according to amino acid sequence QPGLTQPPSVSVAPGQTARITCGGDNIGRKS VHWY QQRPGQAPILVIRDDRD RPSGIPERFSGSSSVNTATLIISR VEAGDEADY YCQVWDSSSKHY VFGPGTKV TALG (SEQ ID NO: 154).

10 . The engineered immune cell of claim 1 , wherein the antibody, or antigen-binding fragment thereof, specific for CD70 is selected from the group consisting of:

a) a VH according to amino acid sequence QVQOLVQOSGGGLVQPRGSLRLSCAASGFTVSNYAMSW VRQAPGKGLEWVAT KSGSDGRTY YADSVKGRFTIARDNSKNSLYLQMNSLRAADTAVYYCAKGIY DVTGSSFDS (SEQ ID NO: 185),

and a VL according to amino acid sequence NFMLTQPHSVSESPGKTVTISCTRSSGSIASNY VQWY QQRPGSAPTTVIYEDN QRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADY YCQSYDSGNRRV (SEQ ID NO: 187);

b) a VH according to amino acid sequence QVQOLVQOSGGGLVQPGGSLRLSCAASGFTFSSYAMSW VRQAPGKGLEWVSLI SGSGGSRY YADSVKGRFTISRDNSKNTLYLQMNNLRAEDTAVY YCARGRG GHGMDV (SEQ ID NO: 181),

and a VL according to amino acid sequence QPGLTQPPSASGTPGQRVTISCSGSSSNIGSNY VYWY QQLPGTAPKLLIYRNN QRPSGVPDRFSGSKSGTSASLAISGLQSEDEADY YCAAWDDSLNGLYV (SEQ ID NO: 182);

c) a VH according to amino acid sequence QVQLVQSGAEVKKPGSSVK VSCRSSGGTFSSQAFSW VRQAPGQGLEWMG RUPFFGVPTY AQRFQGRVTITADKSPTTAYMELTSLRSDDTAVY YCAVLKG RGNFDF (SEQ ID NO: 183),

and a VL according to amino acid sequence DIVMTQSPDSLAVSLGERATINCKSS YS VFHSPNNKNYLAW YQQRPGQPPK LLIYWASTRGSGVPDRFSGSGSGTDFTLTISSLEPEDFAVY YCQQRSNWPLT (SEQ ID NO: 184);

d) a VH according to amino acid sequence QVQOLVOQSGGGLVQPRGSLRLSCAASGFTVSNYAMSWVRQAPGKGLEWV ATKSGSDGRTY YADS VKGRFTIARDNSKNSLYLQMNSLRAADTAVYYCA KGIYDVTGSSFDS (SEQ ID NO: 185), and a VL according to amino acid sequence SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVMFE DSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADY YCYSTDSSGNHKV (SEQ ID NO: 186);

e) a VH according to amino acid sequence EVOLVESGGGV VQPGRSLRLSCAASGFT VSTSHMSW VRQAPGKGLEWLS GKDSGGKTYY ADS VRGRFTIARDDSLNTVFLQMNNMRDEDSGVY YCAR ARPSDPYDGSGFDAFDI (SEQ ID NO: 188),

and a VL according to amino acid sequence SYELTQPPSVSKGLROTATLTCTGNSNNVGNQGAAWLQQHQGHPPKLLS YRNNNRPSGISERFSASRSGNTASLTITGLQPEDEADY YCSAWDSSLSAW V (SEQ ID NO: 189); and

f) a VH according to amino acid sequence QVQLVQSGGGLVKPRGSLRLSCAASGFIFSD Y YMSWIRQAPGKGLQWVA SIRSRRGETNY ADSVKGRFTIARDNAEKSLYLQMNSLRAEDAAVYYCAR HRKSFTDLDAFDL (SEQ ID NO: 190),

and a VL according to amino acid sequence DIVMTQSPSTLSASVGDRVTITCRASQDIGTDLSWY QQKPGKAPKLLIYK ASSLESGVPSRFSGSGSGTDFTLTISSLQPDDFATY YCQHENNYPAT (SEQ ID NO: 191.

Assignments (2)

CONFIRMATORY LICENSE Recorded Jan 6, 2022

From: DANA-FARBER CANCER INST

To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY

Reel/Frame 058571/0341 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021

From: MARASCO, WAYNE A.; ZHU, QUAN KAREN; WANG, YUFEI; CHANG, MATTHEW

To: DANA-FARBER CANCER INSTITUTE, INC.

Reel/Frame 058462/0202 →

Continuity (3)

Provisional Application 62773885 · Nov 30, 2018

Provisional Application 62826462 · Mar 29, 2019

Related Publication 20220047634A1 · Feb 17, 2022

References Cited (93)

US 4683202A · Mullis · 1987 [cited by applicant]

US 4797368A · Carter et al. · 1989 [cited by applicant]

US 4946778A · Ladner et al. · 1990 [cited by applicant]

US 5091513A · Huston et al. · 1992 [cited by applicant]

US 5132405A · Huston et al. · 1992 [cited by applicant]

US 5139941A · Muzyczka et al. · 1992 [cited by applicant]

US 5928906A · Hubert et al. · 1999 [cited by applicant]

US 5994136A · Naldini et al. · 1999 [cited by applicant]

US 6013516A · Verma et al. · 2000 [cited by applicant]

US 8329178B2 · Marasco et al. · 2012 [cited by applicant]

US 8466263B2 · Marasco et al. · 2013 [cited by applicant]

US 9765149B2 · Silence et al. · 2017 [cited by applicant]

US 20180030147A1 · Marasco · 2018 [cited by applicant]

US 20180111992A1 · Fry et al. · 2018 [cited by applicant]

US 20180334490A1 · Brogdon · 2018 [cited by examiner]

US 20190031759A1 · Reiter · 2019 [cited by examiner]

WO WO2007065027A2 · 2007 [cited by applicant]

WO WO2009086514A1 · 2009 [cited by applicant]

WO WO2011139375A1 · 2011 [cited by examiner]

WO WO2013123061A1 · 2013 [cited by applicant]

WO WO2013166500A1 · 2013 [cited by applicant]

WO WO2016057488A1 · 2016 [cited by applicant]

WO WO2016100980A1 · 2016 [cited by applicant]

WO WO2016100985A2 · 2016 [cited by applicant]

WO WO2016178779A1 · 2016 [cited by applicant]

WO WO2017075537A1 · 2017 [cited by applicant]

WO WO2018152181A1 · 2018 [cited by applicant]

WO WO2018156802A1 · 2018 [cited by applicant]

WO WO2019178356A1 · 2019 [cited by applicant]

Adam P. J et al., “CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding”, British Journal of Cancer, Nature Publishing Group UK, London, (Aug. 7, 2006), … [cited by applicant]

Ausubel, F. M., et al. “Current protocols in molecular biology, vol. 1 John Wiley & Sons.” Inc, Brooklyn, New York 3.1 (2003): 1994-2005. [cited by applicant]

Baichwal, Vijay R., and Bill Sugden. “Vectors for gene transfer derived from animal DNA viruses: transient and stable expression of transferred genes.” Gene Transfer. Boston, MA: Springer US, 1986. 117-148. [cited by applicant]

Blömer, Ulrike, et al. “Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector.” Journal of virology 71.9 (1997): 6641-6649. [cited by applicant]

Chen, et al. “Fusion protein linkers: property, design and functionality.” Advanced drug delivery reviews 65.10 (2013): 1357-1369. [cited by applicant]

Cotten, Matt, et al. “High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles.” Proce… [cited by applicant]

Coupar, Barbara EH, Marion E. Andrew, and David B. Boyle. “A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes.” Gene 68.1 (1988): 1-10. [cited by applicant]

Curiel, David T. “High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes.” Natural immunity 13.2-3 (1994): 141-164. [cited by applicant]

Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. Aug. 23, 2016;16(9):566-81. doi: 10.1038/nrc.2016.97. PMID: 27550819; PMCID: PMC5543811. [cited by applicant]

Friedmann, Theodore. “Progress toward human gene therapy.” Science 244.4910 (1989): 1275-1281. [cited by applicant]

GENBANK Accession No. NM_000442.5. [cited by applicant]

GENBANK Accession No. NM_000591.4. [cited by applicant]

GENBANK Accession No. NM_000610.4. [cited by applicant]

GENBANK Accession No. NM_001030288.3. [cited by applicant]

GENBANK Accession No. NM_001123041.2. [cited by applicant]

GENBANK Accession No. NM_001145873.1. [cited by applicant]

GENBANK Accession No. NM_001206609.2. [cited by applicant]

GENBANK Accession No. NM_001328609.2. [cited by applicant]

GENBANK Accession No. NM_001766.3. [cited by applicant]

GENBANK Accession No. NM_001772. [cited by applicant]

GENBANK Accession No. NM_002033.3. [cited by applicant]

GENBANK Accession No. NM_002184.4. [cited by applicant]

GENBANK Accession No. NM_014143.4. [cited by applicant]

GENBANK Accession No. NP_000433.4. [cited by applicant]

GENBANK Accession No. NP_000582.1. [cited by applicant]

GENBANK Accession No. NP_000601.3. [cited by applicant]

GENBANK Accession No. NP_001025459.1. [cited by applicant]

GENBANK Accession No. NP_001116513.2. [cited by applicant]

GENBANK Accession No. NP_001139345.1. [cited by applicant]

GENBANK Accession No. NP_001193538.1. [cited by applicant]

GENBANK Accession No. NP_001315538.1. [cited by applicant]

GENBANK Accession No. NP_001757.1. [cited by applicant]

GENBANK Accession No. NP_001763.3. [cited by applicant]

GENBANK Accession No. NP_002024.1. [cited by applicant]

GENBANK Accession No. NP_002175.2. [cited by applicant]

GENBANK Accession No. NP_054862.1. [cited by applicant]

Grabmaier, Karin, et al. “Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250.” International journal of cancer 85.6 (2000): 865-870. [cited by applicant]

Horwich, A. “Protein import into mitochondria and peroxisomes.” Current Opinion in Cell Biology 2.4 (1990): 625-633. [cited by applicant]

Horwitz, Grunhaus A. “Adenoviruses as cloning vectors.” Semin Virol 3 (1992): 237-252. [cited by applicant]

Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin … [cited by applicant]

International Search report for PCT/US2019/064032 mailed Jul. 15, 2020. [cited by applicant]

Joyner, Alexandra L., William C. Skarnes, and Janet Rossant. “Production of a mutation in mouse En-2 gene by homologous recombination in embryonic stem cells.” Nature 338.6211 (1989): 153-156. [cited by applicant]

Kelleher, Z. T., and J. M. Vos. “Long-term episomal gene delivery in human lymphoid cells using human and avian adenoviral-assisted transfection.” Biotechniques 17.6 (1994): 1110-1117. [cited by applicant]

Lamers, Cor HJ, et al. “Immune responses to transgene and retroviral vector in patients treated with ex vivo- engineered T cells.” Blood, The Journal of the American Society of Hematology 117.1 (2011): 72-82. [cited by applicant]

Lamers, Cor HJ, et al. “Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.” Journal of Clinical Oncology 24.13 (20… [cited by applicant]

Laughlin, C. A., C. B. Cardellichio, and H. C. Coon. “Latent infection of KB cells with adeno-associated virus type 2.” Journal of virology 60.2 (1986): 515-524. [cited by applicant]

Lebkowski, Jane S., et al. “Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types.” Molecular and cellular biology 8.10 (1988): 3988-3996. [cited by applicant]

Liao, Shu-Yuan, et al. “Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney.” Cancer research 57.14 (1997): 2827-2831. [cited by applicant]

Maher, John, et al. “Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRZ/CD28 receptor.” Nature biotechnology 20.1 (2002): 70-75. [cited by applicant]

Mann, Richard, Richard C. Mulligan, and David Baltimore. “Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.” Cell 33.1 (1983): 153-159. [cited by applicant]

McLaughlin, Susan K., et al. “Adeno-associated virus general transduction vectors: analysis of proviral structures.” Journal of virology 62.6 (1988): 1963-1973. [cited by applicant]

Miller, A. D. “Retroviral vectors.” Viral expression vectors (1992): 1-24. [cited by applicant]

Naldini, Luigi, et al. “Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.” Proceedings of the National Academy of Sciences 93.21 … [cited by applicant]

Nicolas, Jean-François, and John LR Rubenstein. “Retroviral vectors.” Vectors (1988): 493-513. [cited by applicant]

Paskind, Michael P., Robert A. Weinberg, and David Baltimore. “Dependence of Moloney murine leukemia virus production on cell growth.” Virology 67.1 (1975): 242-248. [cited by applicant]

Rini, Brian I., Steven C. Campbell, and Bernard Escudier. “Renal cell carcinoma.” The Lancet 373.9669 (2009): 1119-1132. [cited by applicant]

Ryan, M., Kostner, H., Gordon, K et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer 103, 676-684 (2010). https://doi.org/10.1038/sj.bjc.66… [cited by applicant]

Sambrook Joseph and David W. Russell. “Molecular cloning.” A Laboratory Manual 3rd (2001). [cited by applicant]

Suarez, Eloah Rabello, et al. “Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.” Oncotarget 7.23 (2016): 34341-34355. Especially… [cited by applicant]

Temin, Howard M. “Retroviruses and evolution.” Bioscience at the Physical Science Frontier: Proceedings of a Foundation Symposium on the 150th Anniversary of Alfred Nobel's Birth. Totowa, NJ: Humana Press, 1986. [cited by applicant]

Thomas, Kirk R., and Mario R. Capecchi. “Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells.” Cell 51.3 (1987): 503-512.Mansour, et al., Nature (1988) 336, 348-352. [cited by applicant]

Tratschin, Jon-Duri, et al. “A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase.” Molecular and cellu… [cited by applicant]

Written Opinion for PCT/US2019/064032 mailed Jul. 15, 2020. [cited by applicant]

Zufferey, Romain, et al. “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.” Nature biotechnology 15.9 (1997): 871-875. [cited by applicant]